(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2011 (16.06.2011)

PCT

(10) International Publication Number
WO 2011/071871 A1

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2010/059221

(22) International Filing Date:
7 December 2010 (07.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/267,337	7 December 2009 (07.12.2009)	US
61/287,067	16 December 2009 (16.12.2009)	US
61/358,303	24 June 2010 (24.06.2010)	US

(71) Applicant *(for all designated States except US)*: **THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY** [US/US]; 1705 El Camino Real, Palo Alto, California 94306-1106 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KOHRT, Holbrook** [US/US]; 3901 Lick Mill Boulevard #165, Santa Clara, California 95054 (US). **HOUOT, Roch** [FR/FR]; 5, rue Alfred de Musset, F-35700 Rennes (FR). **LEVY, Ronald** [US/US]; 966 Mears Court, Stanford, California 94305 (US). **ALIZADEH, Arash Ash** [US/US]; Stanford University, Department of Medicine, Division of Oncology and Hematology, Lorry Lokey Building, SIM1 Room G2120B, Stanford, CA 94305 (US). **GOLDSTEIN, Matthew J.** [US/US]; 840 Longview Road, Hillsborough, California 94010 (US). **TORCHIA, James** [US/US]; 269 Campus Drive, Stanford, California 94305 (US).

(74) Agent: **SHERWOOD, Pamela J.**; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, California 94303 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/071871 A1

(54) **Title**: METHODS FOR ENHANCING ANTI-TUMOR ANTIBODY THERAPY

(57) **Abstract**: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.